Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study

被引：0
|
作者：
David M Kern
Jill Davis
Setareh A Williams
Ozgur Tunceli
Bingcao Wu
Sally Hollis
Charlie Strange
Frank Trudo
机构：
[1] HealthCore,Department of Medicine, Division of Pulmonary and Critical Care Medicine
[2] Inc.,undefined
[3] AstraZeneca Pharmaceuticals,undefined
[4] AstraZeneca Pharmaceuticals,undefined
[5] AstraZeneca Pharmaceuticals,undefined
[6] Medical University of South Carolina,undefined
来源：
Respiratory Research | / 16卷
关键词：
Chronic obstructive pulmonary disease (COPD); Inhaled corticosteroid/long-acting β; -agonist combinations (ICS/LABA); Comparative effectiveness; Controller treatments; Administrative claims;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies
    Roberts, M. H.
    Borrego, M. E.
    Kharat, A. A.
    Marshik, P. L.
    Mapel, D. W.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 167 - 192
  • [42] Hospital Readmissions Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Arformoterol or Fluticasone/Salmeterol
    Stensland, Mike
    Bollu, Vamsi
    Donohue, James
    CHEST, 2015, 148 (04)
  • [43] Survival among chronic obstructive pulmonary disease patients using fluticasone and salmeterol in combination vs other inhaled steroids and long-acting bronchodilators alone
    Mapel, Douglas W.
    Nelson, Leila S.
    Soriano, Joan
    Davis, Kourtney J.
    CHEST, 2006, 130 (04) : 181S - 181S
  • [44] Evaluation of the Clinical Effectiveness of the Salmeterol/Fluticasone Fixed-Dose Combination Delivered via the Elpenhaler(R) Device in Greek Patients with Chronic Obstructive Pulmonary Disease and Comorbidities: The AEOLOS Study
    Steiropoulos, Paschalis
    Tryfon, Stavros
    Kyriakopoulos, Christos
    Bartziokas, Konstantinos
    Kostikas, Konstantinos
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):
  • [45] Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease
    Asai, Kazuhisa
    Kobayashi, Akihiro
    Makihara, Yukio
    Johnson, Malcolm
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 803 - 811
  • [46] Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database
    Miller, David P.
    Watkins, Stephanie E.
    Sampson, Tim
    Davis, Kourtney J.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 : 467 - 476
  • [47] Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore
    Tee, Augustine
    Chow, Wai Leng
    Burke, Colin
    Guruprasad, Basavarajaiah
    SINGAPORE MEDICAL JOURNAL, 2018, 59 (07) : 383 - 389
  • [48] Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease
    Clerman, Andrew
    Luke, Markham
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (01)
  • [49] Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease
    Feldman, William B.
    Kesselheim, Aaron S.
    Avorn, Jerry
    Russo, Massimiliano
    Wang, Shirley V.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (08) : 1047 - +
  • [50] Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease
    Cazzola, Mario
    Rogliani, Paola
    Matera, Maria Gabriella
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (06) : 775 - 781
12345